Client of a consultant lobbyist
Eli Lilly Canada Inc.
- Meetings this Parliament
- 6
- With MPs
- 0
- Since Nov 2021
- 8
- Active registrations
- 1
Most recent reported meeting: Sep 29, 2026.
Lobbying by Eli Lilly Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Consultant In effect since Aug 16, 2026
Consultant Andre Albinati of Earnscliffe Strategy Group
Consultant lobbyists
-
Andre Albinati
Former public office holder
Formerly Multilateral Trade Policy Advisor to the Minister, Office of the Minister, International Trade (1999–2002)
Formerly Senior Policy Advisor to the Minister, Office of the Minister, Human Resources Development Canada (1998–1999)
Formerly Policy Advisor to the Minister, Office of the Minister, Human Resources Development Canada (1996–1998)
Formerly Policy Advisor to the Minister, Office of the Minister, International Cooperation and Responsible for La Francophonie (1996–1996)
-
Andre Albinati
Former public office holder
Formerly Multilateral Trade Policy Advisor to the Minister, Office of the Minister, International Trade (1999–2002)
Formerly Senior Policy Advisor to the Minister, Office of the Minister, Human Resources Development Canada (1998–1999)
Formerly Policy Advisor to the Minister, Office of the Minister, Human Resources Development Canada (1996–1998)
Formerly Policy Advisor to the Minister, Office of the Minister, International Cooperation and Responsible for La Francophonie (1996–1996)
-
Andre Albinati
Former public office holder
Formerly Multilateral Trade Policy Advisor to the Minister, Office of the Minister, International Trade (1999–2002)
Formerly Senior Policy Advisor to the Minister, Office of the Minister, Human Resources Development Canada (1998–1999)
Formerly Policy Advisor to the Minister, Office of the Minister, Human Resources Development Canada (1996–1998)
Formerly Policy Advisor to the Minister, Office of the Minister, International Cooperation and Responsible for La Francophonie (1996–1996)
Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Great Lakes Pilotage Authority, Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Invest in Canada Hub, Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (10)Hide details
- The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
- Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.
- Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
- Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.
- Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly's business.
- Free trade treaty agreement as it relates to the Canada/US Free Trade Agreement and free trade negotiations as it relates to Columbia, India, and the European Union.
- C-64, An act respecting pharmacare - discussions around the structuring and implementation of a national pharmacare program.
- Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
- Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food & Drug Act.
Registration 775866-289825-17. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Andre Albinati · Consultant
- Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines. Read more
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Andre Albinati · Consultant
- Julie Harb · Policy Advisor, Prime Minister's Office (PMO)
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines. Read more
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Andre Albinati · Consultant
- Miro Froehlich · Director of Policy, Privy Council Office (PCO)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry Read more
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
Free trade treaty agreement as it relates to the Canada/US Free Trade Agreement and free trade negotiations as it relates to Columbia, India, and the European Union.
-
Reported by Andre Albinati · Consultant
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines. Read more
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
Free trade treaty agreement as it relates to the Canada/US Free Trade Agreement and free trade negotiations as it relates to Columbia, India, and the European Union.
-
Reported by Andre Albinati · Consultant
- Niloo Boroun · Director of International Policy, Finance Canada (FIN)
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines. Read more
Free trade treaty agreement as it relates to the Canada/US Free Trade Agreement and free trade negotiations as it relates to Columbia, India, and the European Union.
-
Reported by Andre Albinati · Consultant
- Brandan Rowe · Chief of Staff, Privy Council Office (PCO)
- Miro Froehlich · Director of Policy, Privy Council Office (PCO)
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
-
Reported by Andre Albinati · Consultant
- Jay Allen · Minister (Economic), Global Affairs Canada (GAC)
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines. Read more
Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
Free trade treaty agreement as it relates to the Canada/US Free Trade Agreement and free trade negotiations as it relates to Columbia, India, and the European Union.
-
Reported by Andre Albinati · Consultant
- Jamie Kippen · Chief of Staff, Health Canada (HC)
HealthResearch and Development
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.